#Sweden #Leadership #Lund #Hansa Biopharma #Corporate Affairs

Hansa Biopharma Strengthens Leadership Team

Hansa Biopharma, a pioneering biopharmaceutical company based in Lund, Sweden, has announced the appointment of three new executives set to enhance the company's capabilities and support its ambitious growth strategy. As of August 4, Brian Gorman takes on the role of Chief Legal Officer and Corporate Secretary, bringing over 20 years of global experience in corporate legal matters. Notably, he previously held the position of Chief Legal Officer at Sinclair Pharma Ltd, where he played a vital role in facilitating the company's global expansion. Additionally, Sandra Frithiof will assume the Chief Human Resources Officer position on the same day, coming from Ayvens Sweden AB, where she directed HR efforts for the mobility sector. Her significant background includes building HR organizations and developing human resources strategies that support market entry initiatives.

Furthermore, on September 1, Kerstin Falck Lagercrantz will join Hansa as Vice President of Corporate Affairs, arriving from Pfizer AB where she was Corporate Affairs Director for several years. Her expertise encompasses external communications, crisis management, and influencing health policy. These three appointments signal Hansa Biopharma's commitment to strengthen its leadership in critical areas as it prepares for pre-commercial activities in the U.S. market, which include upcoming Phase 3 data releases and a new Biologics License Application (BLA) submission.

CEO Renée Aguiar-Lucander expressed confidence in the new team's combined experience, stating that their knowledge will be instrumental in navigating the complexities of the biopharmaceutical industry and supporting the company’s growth objectives. Hansa's innovative IgG-cleaving enzyme technology platform aims to address significant unmet medical needs across autoimmune diseases, gene therapy, and transplantation. With imlifidase being a prime example of its pioneering work, the company looks to reshape the treatment landscape for patients with rare immunological conditions.

Hansa Biopharma is listed on Nasdaq Stockholm under the ticker symbol HNSA and continues to build its presence in both European and U.S. markets. For more information about Hansa's products and strategic goals, visit their official website and follow them on Twitter and LinkedIn.

In conclusion, the appointment of experienced executives like Gorman, Frithiof, and Falck Lagercrantz underscores Hansa Biopharma's proactive approach to leadership and innovation in the biopharmaceutical field, positioning the company for future successes and contributions to patient care.